Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Avutometinib, Defactinib and Cetuximab for the Treatment of Patients with Unresectable or Metastatic, Refractory Colorectal Cancer

Trial Status: active

This phase II trial tests how well avutometinib, defactinib and cetuximab works for the treatment of patients with colorectal cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to other places in the body (metastatic) and that has not responded to previous treatment (refractory). Avutometinib and defactinib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Giving avutometinib, defactinib and cetuximab may work better in treating patients with unresectable or metastatic, refractory colorectal cancer.